OncoMed Loses Another Asset – Rosmantuzumab – And CEO Paul Hastings

Loss of anti-RSPO-3 antibody rosmantuzumab, partnered with Celgene, means a rough start to the year, following disappointments in 2017.

Glass broken cracks splinters

OncoMed Pharmaceuticals Inc. started the new year with more bad clinical news – the failure of yet another asset, this time the Celgene Corp.-partnered anti-RSPO3 antibody rosmantuzumab – and the departure of ailing CEO Paul Hastings.

On Jan. 4, the Redwood City, Calif.-based company announced it was terminating a Phase Ia/b program of development of rosmantuzumab,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category